ESC 365 - Cardiovascular benefit of colchicine in relation to baseline risk

ESC Premium Access

Cardiovascular benefit of colchicine in relation to baseline risk

Session: Smaller trials, trial updates, and other studies on inflammation and immunity in cardiovascular disease

Topic: Secondary Prevention

Speaker: Mr N. Mohammadnia (Nijmegen, NL)

Event: ESC Congress 2024

Congress Presentation

About the speaker

Mr N Mohammadnia

Radboud University Medical Centre, Nijmegen (Netherlands (The))

1 presentation

0 follower

7 more presentations in this session

Low-dose interleukin-2 for the reduction of vascular inflammation in acute coronary syndromes (IVORY) / IVORY - Clinical Outcomes And Follow-up (IVORY FINALE) Study

Speaker: Doctor R. Sriranjan (Cambridge, GB)

Anakinra versus placebo double blind Randomized controlled trial for the treatment of Acute MyocarditIS

Speaker: Professor M. Kerneis (Paris, FR)

Colchicine for secondary prevention of stroke and other cardiovascular events: a meta-analysis of randomised trials

Speaker: Mr A. Fiolet (Utrecht, NL)

Effect of pre-hospital pulse-dose glucocorticoid on infarct size in st-segment elevation myocardial infarction: a randomized, blinded, placebo-controlled clinical trial

Speaker: Doctor J. Madsen (Copenhagen, DK)

Randomized double-blind trial to study the benefit of Colchicine in Patients with Acutely Decompensated Heart Failure

Speaker: Professor D. Pascual Figal (Murcia, ES)

Access the full session

Smaller trials, trial updates, and other studies on inflammation and immunity in cardiovascular disease

Speakers: Mr N. Mohammadnia, Doctor R. Sriranjan, Professor M. Kerneis, Mr A. Fiolet, Doctor J. Madsen...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources